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ABSTRACT
Objectives. To compare the pharmacodynamics and tolerabiiity of the new goserelin acetate 10.8-mg depot 
with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy. 
Methods. One hundred sixty patients were randomized in two comparative studies to receive either the
10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 
12 weeks and then the 10.8-mg depot every 12 weeks thereafter. Data for pharmacodynamic assessments 
were collected prospectively, whereas clinical response data were collected retrospectively.
Results. Serum testosterone profiles of the 10.8-mg goserelin acetate depot and the 3.6-mg goserelin ac­
etate depot were sim ilar; testosterone levels in both groups fell below castrate levels by day 21 after ad­
ministration. Decreases in serum prostate-specific antigen level after 3 months of therapy were also similar 
in both groups: 94%  with the 10.8-mg depot and 92.5%  with the 3.6-mg depot. For all patients, the median 
time to progression was 1 52 .7  weeks and the median time to death was 213.6 weeks. The safety profile of 
the 10.8-mg goserelin acetate depot was similar to that of the 3.6-mg depot; hot flashes was the most 
common adverse event. The incidence of injection site reactions was very low (2 [0.3%] of 614 administra­
tions).
Conclusions. The new 10.8-mg depot was pharmacodynamically equivalent to the current 3.6-mg depot and 
was well tolerated, both locally and systemically. The observed times to progression and survival were as 
expected in this patient population. The 10.8-mg gosereiin-acetate depot provided a dosing schedule that 
was convenient for the patient and the physician, and it has the potential to reduce health care costs while 
maintaining the quality of life in patients being treated for advanced prostate cancer. Copyright 1996 by 
Elsevier Science Inc. UROLOGY 48: 894-900 , 1996.
Since the ir  in tro d u c tio n  over a decade ago as a trea tm en t for advanced  prosta te  cancer, lu te in ­
izing ho rm one-re leasing  ho rm one  (LHRH) ago­
nist analogues have displaced estrogens as the 
leading alternative to orchiectom y for patients u n ­
dergoing m o n o th e ra p y ,1 an d  they have em erged as 
a co m p o n en t of com bina tion  therapy  w ith  an tian ­
drogens in  pa tien ts  receiving com bined  androgen
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blockade.2,3 Because the commercially available 
depot form ulations of LHRH analogues for p ros­
tate cancer require adm inistration every 4 weeks, 
developm ent of a convenient, longer-acting depot 
form ulation has long been desired.
A new  longer-acting, 3-m ontli depot form ula­
tion of the LHRH analogue goserelin acetate im ­
plant (Zoladex, Zeneca Pharmaceuticals, W il­
m ington, Del, and Macclesfield, Cheshire, U.K.) 
was recently evaluated in clinical trials conducted 
in patients w ith  advanced prostate cancer. In  a 
Phase II study, effective suppression of serum  con­
centrations of testosterone was achieved and m ain ­
tained for at least 12 weeks following adm inistra­
tion of the 10.8-mg depot form ulation.4 In two 
Phase III s tud ies ,5,6 the pharm acodynam ics, effi­
cacy, and tolerabiiity of the new  10.8-mg form u­
lation were com pared w ith the standard  3.6-mg
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formulation. Effective suppression of serum  tes­
tosterone below the castrate level w ithin 3 weeks 
and m aintenance of suppression for the duration  
of therapy was achieved w ith bo th  the 10.8- and
3.6-mg depot formulations. The 10.8-mg depot 
was well tolerated both  locally and systemically.5,6 
In  this report, we update the pharm acodynam ic 
and safety results of these two Phase III studies 
and present an analysis of prostate-specific antigen 
(PSA) response, time to progression, and survival.
MATERIAL AND METHODS
P a t i e n t  S e l e c t i o n
Patients with histologic confirmation of prostate cancer, ei­
ther locally advanced (T3, T4) or metastatic (M l)  disease, 
with pretreatment serum testosterone within the normal 
range and a life expectancy of more than 6 months were eli­
gible for entry. Patients previously treated with orchiectomy 
or hormonal treatment were excluded. All patients provided 
written informed consent, and the study was approved by the 
appropriate Institutional Review Boards.
S t u d y  D e s i g n
The two multicenter, comparative studies (0001 and 1805) 
were of an identical, open, parallel-group design with a 48- 
week study period. Patients were randomized to one of two 
treatment groups: one group received the 10.8-mg depot for­
mulation at 84-day intervals throughout the study; the other 
group initially received a subcutaneous injection of the 3 .6- 
mg depot formulation of goserelin acetate, and, after three 
administrations at 28-clay intervals, received subcutaneous in­
jections of the 10.8-mg depot formulation at 84-day intervals 
throughout the remainder of the study.
T e s t o s t e r o n e  A s s e s s m e n t s
The primary objective of these studies was to compare the 
pharmacodynamics of the 10.8- and 3 .6-mg goserelin acetate 
depots. The mean testosterone levels achieved during weeks
4  to 12 and at the end of weeks 4, 8 , and 12 were compared 
between the 10.8- and the 3.6-mg treatment groups. In ad­
dition, the serum testosterone levels of individual patients 
were assessed according to secondary criteria for induction 
(defined as testosterone levels falling below Lhe castrate level 
after the first administration) and maintenance (defined as 
serum testosterone levels remaining below the castrate level 
throughout a 12-week administration period).
Serum testosterone analyses were performed in a central 
laboratory, the Urological Research Laboratory (U R L ), at the 
University of Nijmegen, Nijmegen, The Netherlands. Total 
serum testosterone was assessed using a Diagnostic Products 
Corporation (DPC) radioimmunoassay kit (Los Angeles, 
Calif). This kit was previously tested against three other 
methods of testosterone measurement (a radioimmunoassay 
manufactured by Amerslvam, a fluorescence immunoassay 
manufactured by DELPHI A system [ LKB-Pharmacia ], and a 
paper chromatographic analysis [ Endocrinology-KN ]) .  
These assays were compared using a series of testosterone 
levels from two sets of control sera (NMS I, II, and III and 
Lyphocheck [Biorad] I, II, and III). The results of the com­
parisons showed that, in the range of low testosterone levels, 
the variability with the DPC kit was lowest, approximately 
20% (2.46 ±  0.46 nm ol/L). Serum testosterone assay results 
from URL were also compared with results obtained from En­
docrine Sciences Laboratory, Inc (ESL; Calabasas Hills, Calif 
[ESL used a column chromatographic assay]). The compar­
ison was made using samples obtained from 15 patients at the 
Nijmegen University Hospital who were being treated with 
LHRH analogues; these patients w'ere not enrolled in the two 
studies that compared the 10.8- and 3.6-mg goserelin acetate 
depots.
In the current studies that compared the two depots, serum 
testosterone levels were measured before treatment, weekly 
for the first 4 weeks, then every 2 weeks until week 24, and 
then at weeks 36 and 48 (the day of administration of the 
first depot was defined as day 1 ) . On days when sampling 
coincided with depot administration, samples were taken be­
fore administration of the depot. Serum testosterone was re­
corded as the mean value from duplicate assessments of the 
testosterone level of the sample. Internal quality-control sam­
ples (NMS and Lyphocheck) were included each time sam­
ples were assessed. When recorded results on any study day 
were greater than 2 nmol/L, the assessment was repeated and 
the new result was recorded as the testosterone value for that 
day, regardless of whether the new result was higher or lower 
than the original result. This castrate level was defined by 
using testosterone values in the castration range from 10 pa­
tients in a previous study with the goserelin acetate 10.8 -mg 
depot. The mean testosterone value (0.95 nm ol/L) obtained 
from these patients plus two standard deviations (two times
0,55 nm ol/L) was used to arrive at the castrate level of 2.0 
nmol/L.
E f f i c a c y  E v a l u a t i o n s
Data for PSA, time to progression, and survival were col­
lected retrospectively by the Trialbureau Urology in Nijmegen 
and verified against hospital records. PSA results were com­
pared between the 3.6- and 10.8-mg depots but only up until
3 months of therapy, because all patients received the 10.8- 
mg depot after that point. Results for time to progression and 
survival were combined for the two treatment groups to give 
an overview of disease outcome for these patients.
Changes in serum PSA alone were not considered evidence 
of disease progression. However, increases in PSA levels with 
subjective evidence of progression was considered evidence 
of progression.
Any one of the following was considered progression:
1. An increase greater than 50% in the value obtained when  
the largest diameter in one or more measurable lesions is mul­
tiplied by its longest perpendicular diameter
2. New soft-tissue metastasis
3. New osteolytic lesions or an increase of 25% or more in 
the size of existing osteolytic metastases
4. New “hot spots” on bone scintigraphy
For changes in PSA levels, stabilization was defined as an 
increase of greater than or equal to 50% of the baseline level 
confirmed by two assessments not less than 2 weeks apart. A 
PSA increase was defined as an increase greater than 4 ng/mL 
in patients who previously had a complete response, or an 
increase greater than 50% of the baseline level in patients who 
previously had a partial response, each confirmed by two as­
sessments 2 weeks apart.
Any o f  the following was considered evidence of subjective 
progression:
1. Cancer-related decrease of greater than 25% of the he­
moglobin measurement or the need for more than two blood 
transfusions a month
2. A cancer-related weight loss greater than 15%
3. A cancer-related increase in the performance-pain-anal- 
gesic-performance score
Sa f e t y  E v a l u a t i o n s
All patients who received study treatment were included in 
the safety evaluation. Adverse events were recorded at each
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visit until patients completed their randomized therapy. Pa­
tients were solicited indirectly for adverse events; prompted 
by a question, each patient described anything that had both­
ered him since his last visit. In addition, any event considered 
by an investigator to be an adverse event was recorded.
S t a t i s t i c a l  A n a l y s i s
Mean testosterone level was the primary end point and was 
analyzed statistically between weeks 4 and 12 and at the end 
of weeks 4, 8 , and 12. Analysis of variance (ANOVA) was 
used to compare mean testosterone levels between the 10.8- 
mg depot and the 3 .6 -mg depot for each o f  the two studies 
separately; the results were then pooled. One hundred fifty- 
six patients were analyzed using the intent-to-treat approach. 
Possible sources of variation of study, center within study, 
treatment, study by treatment interaction, and center by treat­
ment interaction were taken into account.
Successful induction required at least one sample value be­
ing below the castrate level after the first depot. For successful 
maintenance, all patients receiving at least one depot were 
required Lo have no sample levels above the castrate level 
within 84 days of a depot administration, excluding the in­
duction period for the first deppt. A 95% confidence interval 
was derived for the difference in the percentage maintenance 
rates between the two treatment groups to assess the precision 
of this comparison.
The percent fall in PSA from the baseline value after 3 
months of study treatment was calculated. The number and 
percentage of patients whose PSA values were elevated 
(greater than 4 ng/m L) at baseline and fell to within the nor­
mal range at month 3 were tabulated and compared between 
the two treatment groups.
Time to progression and lime to death were estimated using 
the methods of Kaplan and Meier. Time to progression was 
defined as the number of days from the administration of the 
first goserelin acetate depot to the date of documentation of 
progression or death without progression. The time to death 
was defined as the number of days from the time of admin­
istration of the first goserelin acetate depot to the date of death 
from any cause. Data from patients who neither progressed 
nor died were censored at the time of their last visit to the 
clinic.
RESULTS
D e m o g r a p h y  a n d  Pa t i e n t  C h a r a c t e r i s t i c s
The age an d  body  w eight of patien ts from both 
trea tm en t g roups in  b o th  studies w ere similar at 
en try  (T ab le  I ) .  O f the 80 patien ts  entered into 
each s tu d y — betw een  M arch  10, 1990, and Ju ly  8, 
1992— 67 (8 4 % ) pa tien ts  in  s tudy  0001 and 66 
(8 3 % ) patien ts  in  s tudy  1805 w ere  over 65 years 
of age.
T e s t o s t e r o n e  A s s e s s m e n t s
M ean testosterone levels be tw een  weeks 4 and 
12 and  at the en d  of w eeks 4, 8, and  12 were below 
the castrate level; there  w ere no significant differ­
ences betw een  the  10.8- an d  3 .6 -m g treatm ent 
groups (T able  I I ) .
F igure 1 illustra tes the m ean  se ru m  testosterone 
profile achieved in  the  two trea tm en t groups. The 
profiles w ere sim ilar for b o th  groups, w ith  testos­
terone levels falling below  the castrate level by  day 
21 and  then  rem ain ing  below  the castrate level un-
TABLE I. Dem ographic and p re tre a tm e n t  
characteristics
Treatment Group
3.6-mg 
Depot 
(n = 83)
t 0.8-mg 
Depot 
(n = 77)
Age (yr)
Mean 72 73
Range 52-89 49-88
Weight (kg)
Mean 76 77
Range 48-108 53-105
Stage (TMN classification)
TO 0 2
T1 0 2
T2 7 21
T3 46 38
T4 26 1 1
Tx 4 3
M0 28 25
M1 43 44
Mx 12 8
G1 15 9
G2 38 38
G3 26 26
Gx 4 4
TABLE 11. T esto s teron e  leve l su ppression
(nmol/L)*
Treatment Group
3,6-mg 10.8-mg
Depot Depot
Weeks of Treatment (n = 83) (n = 77)
Week 0 17.91 ± 6.99 18.48 ± 6.35
(n = 75) (n = 75)
Week 4 1.05 ± 2.04 0.92 ± 0.47
(n = 76) (n = 73)
Week 8 0.60 ± 0.39 0.62 ± 0.49
(n = 70) (n = 70)
Week 12 0.60 ± 0.36 0.73 ± 0.69
* Mean ±  standard deviation.
(n = 65) (n = 69)
til week 12. Beyond w eek 12, w hen both  groups 
were receiving the 10.8-mg depot, levels achieved 
in bo th  groups were m aintained below the castrate 
level.
Adequate suppression of testosterone was m ain­
tained in 99.4% of the patients. Only 1 (0 .6% ) 
patient did no t have adequate suppression during 
therapy; this patient received the 10.8-mg depot. 
In 8 other patients, a transient elevation in  testos­
terone levels above the castrate level was followed 
by a re tu rn  w ith in  14 days to levels w ith in  the 
castrate range. The clinical outcom e for these pa-
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tients was similar to that observed for the rest of 
the patients in these studies.
Figure 2 shows the results of the com parison of 
assay results from URL and  ESL. URL reported 
higher testosterone levels for all samples, indicat­
ing a clear difference between the two testosterone 
assays.
E f f i c a c y
PSA results were available at baseline and at 12 
weeks for 54 of the 83 patients in  the 3.6-mg group 
and 54 of the 77 patients in the 10.8-mg group. 
The percentages of patients w ith  PSA values that 
fell to w ithin the norm al range following 3 m onths 
of study treatm ent were similar between treat­
ments: 26 (48% ) of 54 patients treated w ith  the
3.6-mg depot and 28 (52% ) of 54 patients treated 
w ith  the 10.8-mg depot. The m edian percentage 
fall in serum  PSA was also similar in both  groups: 
92.5% for those treated w ith  the 3.6-mg depot and 
94.0% for those treated w ith the 10.8-mg depot.
One hundred  five (66% ) of the 160 patients had 
progressed at the time of this analysis. The m edian 
time to progression was 152.7 weeks. The Kaplan- 
Meier probability of progression is presented in 
Figure 3.
Eighty-three (52% ) of the 160 patients had died 
at the time of this analysis. Fifty-three (64% ) of
the 83 patients w ho had died d id  so as a resu lt of 
prostate cancer alone, 25 (3 0 % ) died as a resu lt of 
other causes, and  5 (6% ) died as a resu lt of u n ­
know n causes; the observed causes of death  were 
no t unexpected  in this p a tien t popu la tion , and  
none of the deaths w ere a ttr ib u ted  to treatm ent. 
The m edian tim e to d ea th  w as 213.6 weeks. The 
Kaplan-Meier p robab ility  of death  is p resen ted  in  
Figure 4.
Safety
D uring  the com parative phase (w eeks 0 th rough  
1 2 ), the  only adverse event rep o rted  in m ore than  
5% of patients was h o t  flashes, w ith  an incidence 
of 47% in  the 10.8-m g g roup  an d  48% in the  3.6- 
m g group. Adverse events occurring  in  m ore than  
5% of patients d u r in g  the  noncom para tive  phase 
(w eeks 12 th rough  4 8 )  are p resen ted  in  Table 111. 
Only 1 patien t h ad  an  adverse event that led to 
w ithdrawal; the  p a tien t h ad  m ild  p ru ritu s  from  
paraneoplastic derm atitis  w hile  h e  was receiving 
the 10.8-mg depo t p rep ara tio n  of goserelin. The 
adverse event w as considered  un re la ted  to therapy 
w ith  10.8-m g goserelin . T u m o r flare was reported  
in  6 patients, in c lu d in g  4 in  the  3 .6-m g treatm ent 
group and 2 in  the  10.8-m g trea tm en t group. One 
patien t in  each g roup  h ad  a sp inal cord com pres­
sion: 1 pa tien t h ad  m edu llary  com pression  8 days
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COMMENT
The com bined results from the two studies, 
w hich include data from a total of 160 patients, 
dem onstrate that the 10.8-mg depot form ulation 
of goserelin acetate is pharm acodynam ically 
equivalent to three consecutive adm inistrations of 
the 3.6-mg depot, w ith regard to induction  and 
m aintenance of serum  testosterone suppression. 
Adequate suppression of serum  testosterone was 
m aintained in 99.4% of the patients. D uring treat­
m ent, 9 patients had  at least one serum  testoster­
one value above the castrate level of 2.0 nm ol/L , 
eight of w hich were transient and isolated; how ­
ever, the clinical outcom e of these patients, as 
measured by time to progression and survival, was 
no different from that of the rest of the patients in 
these studies. Only 1 patient was considered to
FIGURE 2. Comparison o f serum testosterone levels have  failed in itia l t re a tm e n t w ith  gosere lin  ace ta te
reported by the Urological Research Laboratory (URL) 
and Endocrine Sciences Laboratory (ESL),
for part of the treatm ent period; the resultant fail­
ure rate of 0.6% (1 of 160) was considered ac­
ceptable. Ultimately, w ith the continued adm in­
istration of goserelin acetate during the follow-up 
after receiving the first goserelin  3 .6-m g depot; an- period, this pa tien t’s serum  testosterone level was 
o ther p a tien t had  sp inal cord com pression  on  the adequately suppressed and the clinical course of
sam e day as the first adm in is tra tion  of the 10.8- 
m g goserelin  depot. B oth  events w ere considered 
by the investigator to be re la ted  to disease pro-
his disease was considered by the investigator no t 
to have been adversely affected.
The difference in results between the URL and
gression. O nly  2 (0 .3% ) of 614 adm in istra tions of ESL testosterone assays underline the im portance 
the  10.8-m g d ep o t re su lted  in  local reactions; bo th  of defining the castrate level using the local patient
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TABLE III. A d v e rse  e v en ts  re p o r te d  in m ore  
than 5%  o f  p a tie n ts  during the  noncom parative  
p h a se , w eek s  12 to  4 8  (n = 157)
Adverse Event 10.8-mg Depot
Hot flashes 100 (64%)
Pain 22 (14%)
Gynecomastia 13 (8%)
Pelvic pain 10 (6%)
Bone pain 9 (6%)
population  and assay. It also suggests that choos­
ing a different castrate level (for example, from 
literature references) may lead to different conclu­
sions, depending on the actual assay used.
The m edian time to progression (152.7 weeks) 
and  m edian survival time (213*6 w eeks) w ith  the
10.8-mg depot were longer than  those previously 
reported  w ith the 3.6-mg depot. Kaisary et a V  re­
ported  a m edian time to treatm ent failure of 26.9 
weeks and a m edian survival time of 110 weeks, 
w hereas Vogelzang et al.8 reported m edian times 
to treatm ent failure and survival of 52 and  119 
weeks, respectively; bo th  used  the 3.6-mg depot. 
The differences betw een the previously published 
reports and the current studies may be due to dif­
ferent patient populations; whereas the previous 
reports mainly studied patients with metastatic 
prostate cancer, the current studies included pa­
tients w ith  bo th  locally advanced and metastatic 
disease.
The adverse event profile of the 10.8-mg goser­
elin depot was similar to that of the 3.6-mg depot.
The 10.8-mg depot w as well to lerated, and  the in ­
cidence of injection site reactions was low  (0 .3 % ). 
T um or flare was rep o rted  in  6 pa tien ts  (4  in  the
3.6-m g group and  2 in  the 10.8-m g g ro u p ) ,  b u t 
none of the patients w ithd rew  because of this ad­
verse event. It is possible th a t coadm in istra tion  of 
an tiandrogen therapy w ith  LHRH-A therapy could  
have prevented  or lessened the severity of tu m o r 
flare in  these patients.
The 10.8-mg goserelin-acetate depo t is an ac­
ceptable and effective m e th o d  for suppressing  se­
rum  testosterone levels, p rov id ing  a dosing sched­
ule that is convenien t for the pa tien t an d  the 
physician and th a t coincides w ith  the rou tine  care 
of patients w ith  advanced  p rosta te  cancer. The
10.8-mg depot also has the  po ten tia l to reduce 
health  care costs by red u c in g  the n u m b er of health  
care provider contacts, w hile  m ain ta in ing  the 
quality of life of pa tien ts  being  treated for ad­
vanced prostate cancer.
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